New therapy shows potential in slowing Alzheimer’s

For years scientists have recognized a connection between plaque deposits on the brain and the progression of Alzheimer’s disease. Plaque deposits are formed when amyloid precursor protein (APP), found widely throughout the body, releases itself into fragments, called beta-amyloids, which in turn form plaque.

While other scientists have been researching ways to prevent plaque from depositing, the University of Florida team sought to reduce plaque by using a naturally occurring human-binding protein, gelsolin, to absorb the beta-amyloids, like a sponge. Preliminary data from the US National Institute of Aging-sponsored research reveals that gelsolin has succeeded in reducing amyloid deposition by as much as two-thirds to three-quarters.

“We are excited by the preliminary results,” said Dr Jeffrey Hughes of the University of Florida College of Pharmacy. “We look forward to further testing our approach to see if gelsolin continues to act as a sponge, absorbing and reducing plaque and ultimately affecting the progression of Alzheimer’s disease.”